NASDAQ:BGMS

Cyclacel Pharmaceuticals Q2 2026 Earnings Results & Report

Cyclacel Pharmaceuticals logo
$0.61 +0.04 (+6.28%)
Closing price 03:59 PM Eastern
Extended Trading
$0.65 +0.04 (+7.06%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cyclacel Pharmaceuticals reported Q2 2026 earnings on August 14, 2026. The company reported EPS of -$0.08, while revenue was $336 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Cyclacel Pharmaceuticals EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cyclacel Pharmaceuticals Revenue Results

Actual Revenue
$336 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cyclacel Pharmaceuticals Q2 2026 Earnings FAQ

Cyclacel Pharmaceuticals (NASDAQ:BGMS) reported earnings of -$0.08 per share for Q2 2026. The report was announced on Friday, August 14, 2026.

Cyclacel Pharmaceuticals reported revenue of $336 thousand for Q2 2026.

Cyclacel Pharmaceuticals Earnings Headlines

Cyclacel Pharmaceuticals (NASDAQ:BGMS) Stock Falls 9.3% - Should You Sell?
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Cyclacel Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclacel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your email.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (NASDAQ:BGMS) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research has centered on compounds that target cell-cycle regulation and other processes involved in cancer-cell growth.

The company’s investigational drug candidates have included fadraciclib, a cyclin-dependent kinase inhibitor, and sapacitabine, an oral nucleoside analogue. These candidates have been studied for potential use in hematologic cancers and solid tumors; they are not approved medicines.

Founded in the United Kingdom, Cyclacel has operated in both the U.K. and the United States. Spiro Rombotis has served as the company’s president and chief executive officer.

View Cyclacel Pharmaceuticals Profile